Iovance Biotherapeutics, Inc.
IOVA
$6.98
$0.467.06%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 65.65% | 44.82% | 17.74% | 15.20% | 92.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 65.65% | 44.82% | 17.74% | 15.20% | 92.73% |
| Cost of Revenue | -10.81% | -0.51% | 14.08% | 22.08% | 55.83% |
| Gross Profit | 403.28% | 337.77% | 21.60% | 7.18% | 4,325.57% |
| SG&A Expenses | 4.54% | -11.08% | -13.99% | -12.15% | -5.06% |
| Depreciation & Amortization | 1.60% | 5.88% | 3.98% | -7.44% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.96% | -10.60% | -0.02% | 6.50% | 30.60% |
| Operating Income | 54.38% | 33.14% | 15.15% | -0.78% | -11.64% |
| Income Before Tax | 55.60% | 32.45% | 6.86% | -10.11% | -11.27% |
| Income Tax Expenses | -169.06% | 63.82% | -88.19% | -58.22% | 236.35% |
| Earnings from Continuing Operations | 57.63% | 31.95% | 8.47% | -9.23% | -14.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.63% | 31.95% | 8.47% | -9.23% | -14.99% |
| EBIT | 54.38% | 33.14% | 15.15% | -0.78% | -11.64% |
| EBITDA | 59.39% | 35.93% | 12.46% | 0.62% | -11.75% |
| EPS Basic | 68.51% | 47.50% | 31.43% | 9.00% | 2.08% |
| Normalized Basic EPS | 67.01% | 48.11% | 35.81% | 13.29% | 5.27% |
| EPS Diluted | 68.51% | 47.50% | 31.43% | 9.00% | 2.08% |
| Normalized Diluted EPS | 67.01% | 48.11% | 35.81% | 13.29% | 5.27% |
| Average Basic Shares Outstanding | 34.58% | 29.62% | 33.48% | 20.04% | 17.45% |
| Average Diluted Shares Outstanding | 34.58% | 29.62% | 33.48% | 20.04% | 17.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |